Ipilimumab: all 592 studies that test it

Page 1 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879599Phase 2/3
• Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879586Phase 2/3
• Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingNCT07838974Phase 1
• Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2
• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2
• Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingNCT07689175Phase 2
• Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell CarcinomaRecruitingNCT07611825Phase 2
• VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingNCT07504796Phase 2
• Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 1
• A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingNCT07444619Phase 1
• A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicable
• Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2
• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2
• The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingNCT07338981Phase 3
• A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingNCT07291076Phase 1/2
• Neo-adjuvant Immunotherapy in Patients With Localized MelanomaRecruitingNCT07230613Phase 2
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingNCT07188896Phase 2
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialRecruitingNCT07155317Phase 2
• A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.RecruitingNCT07134842Phase 1
• Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)RecruitingNCT06999980Phase 2
• NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2
• Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Phase 2
• SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1
• SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaRecruitingNCT06794775Phase 3
• Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingNCT06747845Phase 2
• Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingNCT06712927Phase 2
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingNCT06594991Phase 2
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingNCT06581406Phase 2/3
• PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesRecruitingNCT06519266Phase 3
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
• The Sagittarius TrialRecruitingNCT06490536Phase 3
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2
• CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2
• NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialRecruitingNCT06342037Phase 2
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
• Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2
• Immunotherapy in Patients With Early dMMR Rectal CancerRecruitingNCT05732389Phase 2
• Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaRecruitingNCT05647265Phase 2
• Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeNot yet recruitingNCT05597800Phase 2
• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsRecruitingNCT05584670Phase 1/2
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
• Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaRecruitingNCT05498792Early Phase 1
• Nivolumab-ipilimumab and Chemoradiation for Cervical CancerRecruitingNCT05492123Phase 2
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2
• Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCRecruitingNCT05310643Phase 2
• Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2
• Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerRecruitingNCT05088889Phase 1
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2
• Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaRecruitingNCT04823403Phase 1
• Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingNCT04741438Phase 3
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaRecruitingNCT04248569Phase 1
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
• Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2
• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaRecruitingNCT03406247Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma PatientsRecruitingNCT03166397Phase 2
• SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingNCT03138161Phase 1/2
• Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingNCT03026140Phase 2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2TerminatedNCT06790303Phase 2Results posted
• Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaTerminatedNCT05921760Phase 1/2Results posted
• A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCompletedNCT05407675Phase 1/2Results posted
• Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results posted
• A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaCompletedNCT05041062Phase 2Results posted
• Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results posted
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results posted
• FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedNCT04894994Phase 2Results posted
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant MesotheliomaTerminatedNCT04840615Phase 1Results posted
• Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaTerminatedNCT04635735Phase 1/2Results posted
• T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedNCT04611126Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results posted
• Neoadjuvant Immunotherapy in Brain MetastasesTerminatedNCT04434560Phase 2Results posted
• Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 2Results posted
• Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results posted
• A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results posted
• Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results posted
• Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT04118166Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results posted
• BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver CancersCompletedNCT04021043Phase 1/2Results posted
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results posted

← Ipilimumab overview